RT Journal Article
SR Electronic
T1 Epigenetic regulation of differentially expressed Drug-metabolizing enzymes in cancer
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP DMD-MR-2020-000008
DO 10.1124/dmd.120.000008
A1 Jiaqi Wang
A1 Yu Lushan
A1 Huidi Jiang
A1 Xiaoli Zheng
A1 Su Zeng
YR 2020
UL http://dmd.aspetjournals.org/content/early/2020/06/29/dmd.120.000008.abstract
AB Drug metabolism is a biotransformation process of drugs, catalyzed by drug-metabolizing enzymes (DMEs) including phase I DMEs and phase II DMEs. The aberrant expression of DMEs occurs in the different stages of cancer. It can contribute to the development of cancer and lead to individual variations in drug response by affecting the metabolic process of carcinogen and anticancer drugs. Apart from genetic polymorphisms, the one we know the most about, current evidence indicates that epigenetic regulation is also central to the expression of DMEs. This review summarizes differentially expressed DMEs in cancer and related epigenetic changes, including DNA methylation, histone modification, and non-coding RNAs (ncRNAs). Exploring the epigenetic regulation of differentially expressed DMEs can provide a basis for implementing individualized and rationalized medication. Meanwhile, it can promote the development of new biomarkers and targets for the diagnosis, treatment, and prognosis of cancer.